New Chief Financial Officers Appointed at Carl Zeiss AG and Carl Zeiss Meditec AG
"With the appointment of Dr. Christian Müller, a successful manager with extensive experience within the ZEISS Group will assume the role of Chief Financial Officer at Carl Zeiss AG," explained Prof. Dr. Dieter Kurz, Chairman of the Supervisory Board of Carl Zeiss AG.
The Supervisory Board of Carl Zeiss Meditec AG has decided to appoint Justus Felix Wehmer as CFO of Carl Zeiss Meditec AG, also effective 1 October 2018. Mr. Wehmer is currently CFO and Co-Head of the Microscopy business group at the ZEISS Group.
In addition, effective 1 October 2018, the Management Board of Carl Zeiss Meditec AG will be expanded from two to three Members with the appointment of Jan Willem de Cler. Mr. de Cler has been at ZEISS since 2004 and currently heads Surgical Ophthalmology within the Medical Technology business group. As Member of the Management Board, his responsibilities will include Human Resources and Employee Development.
"We are particularly pleased that we were able to appoint three long-time employees from the ZEISS Group to these positions. This demonstrates that our leadership development is quite effective," said Prof. Dr. Michael Kaschke, President & CEO of Carl Zeiss AG and Chairman of the Supervisory Board of Carl Zeiss Meditec AG.
The respective Supervisory Boards would like to wish Dr. Christian Müller, Justus Felix Wehmer and Jan Willem de Cler much success in their new positions. The Supervisory Board and the Executive Board of Carl Zeiss AG would also like to thank Thomas Spitzenpfeil for his commitment and many years of successful cooperation, and wish him all the best and much success in his personal and professional future.
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.